About one-third of patients with ovarian cancer who wouldn't be expected to respond to a PARP inhibitor had partial shrinkage of their tumor when a kinase inhibitor was added to treatment, report scientists from Dana-Farber ...
Apr 3, 2017
0
2
(HealthDay)—Zejula (niraparib) has been approved by the U.S. Food and Drug Administration to treat adult women with recurring cancers of the ovaries, fallopian tubes or abdominal wall (peritoneum) whose tumors have shrunk ...
Mar 28, 2017
0
0
(HealthDay)—For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online ...
Feb 21, 2017
0
0
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress ...
Oct 8, 2016
0
4
The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. ...
Sep 23, 2016
0
2
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:
May 20, 2016
0
78
A research team led by Jackson Laboratory (JAX) President and CEO Edison Liu, M.D., have found a molecular fingerprint of some of the most deadly cancers of women: a genomic configuration described as a tandem duplicator ...
Apr 4, 2016
0
24
Background: Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer. "In this study, we assessed whether a novel immunotherapeutic approach that we ...
Nov 18, 2015
0
24
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known ...
Nov 4, 2015
0
159
(HealthDay)—The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed despite platinum-based chemotherapy.
Oct 12, 2015
0
16
